Scandion Oncology A/S (STO:SCOL)

Scandion Oncology Income Statement

Financials in millions DKK. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Selling, General & Admin	21.83	13.95	17.16	8.45	3.09
Research & Development	19.32	31.63	65.07	47.71	21.67
Other Operating Expenses	-	0.22	-	-	-
Operating Expenses	41.15	45.8	82.22	56.16	24.76
Operating Income	-41.15	-45.8	-82.22	-56.16	-24.76
Interest Expense	-0.01	-0.04	-0.5	-0.77	-0.04
Interest & Investment Income	0.34	0.13	0	-	-
Currency Exchange Gain (Loss)	-0.1	0.56	-1.54	-1.08	2.28
Other Non Operating Income (Expenses)	-0	0.45	2.06	0.8	1
Pretax Income	-40.91	-44.7	-82.2	-57.21	-21.52
Income Tax Expense	-4.25	-5.5	-5.5	-5.51	-4.38
Net Income	-36.66	-39.2	-76.7	-51.71	-17.14
Net Income to Common	-36.66	-39.2	-76.7	-51.71	-17.14
Shares Outstanding (Basic)	235	41	41	32	20
Shares Outstanding (Diluted)	235	41	41	32	20
Shares Change (YoY)	476.72%	-	26.67%	63.87%	30.32%
EPS (Basic)	-0.16	-0.96	-1.88	-1.61	-0.87
EPS (Diluted)	-0.16	-0.96	-1.88	-1.61	-0.87
Free Cash Flow	-27.52	-50.67	-69.86	-50.12	-17.27
Free Cash Flow Per Share	-0.12	-1.25	-1.72	-1.56	-0.88
EBITDA	-40.99	-45.53	-82.08	-56.1	-24.72
D&A For EBITDA	0.16	0.27	0.14	0.07	0.04
EBIT	-41.15	-45.8	-82.22	-56.16	-24.76

Updated Mar 12, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.